Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52%
Monday, October 5, 2026 · 10 min
Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's benefits across frailty levels.
Listen
Show notes
Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's benefits across frailty levels.
In this episode
- Rhode Island Medicaid Ends Coverage of Wegovy,… — Inkl
# Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss Author: Cole Mercer Published: 2026-10-03T12:50:36Z Source: medicaldaily.com Language: en ## Story Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss Oct 03, 08:50 am EDT [Medical…
- GLP-1 use for weight loss plunges 52% in Massachusetts after insurers cut coverage — Morgan Taylor
Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients - CRBC News # Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients Morgan Taylor| The Cool Down Oct 3• 3 min read 2 Save Massachusetts saw a 52% decline in GLP‑1 use for weight loss between 2025 and Q1 2026 after multiple commercial and state…
- OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage — PR Newswire
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage # OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage Obesity Action Coalition Oct 02, 2026, 08:15 ET TAMPA, Fla., Oct. 2, 2026 /PRNewswire/ -- The Obesity Action Coalition (OAC) is calling on Cigna to listen to its employees and reconsider its decision to end coverage of GLP-1 medications for weight…
- I'm an obesity expert and can't wait for the compounding craze to stop | Fortune — Adonis Saremi
# I'm an obesity expert and can't wait for the compounding craze to stop | Fortune Author: Adonis Saremi Published: 2026-10-03T11:30:00Z Source: fortune.com Language: en ## Story I'm an obesity expert and can't wait for the compounding craze to stop | Fortune # I’m an obesity expert and can’t wait for the compounding craze to stop By Adonis Saremi October 3, 2026, 7:30 AM ET Dr. Adonis…
- Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network — Samantha Anderer
Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network # Semaglutide Demonstrates Benefits Across Frailty Levels Samantha Anderer Article Information Published Online: October 2, 2026 The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology…